Recent News

• 09.10.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.22.2025 - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
• 08.11.2025 - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
• 06.10.2025 - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
• 05.29.2025 - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Recent Filings

• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.26.2025 - 3 Initial statement of beneficial ownership of securities
• 08.22.2025 - 8-K Current report
• 08.22.2025 - EX-99.1 EX-99.1
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - 8-K Current report
• 08.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities